BICYCLE THERAPEUTICS PLC

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(In thousands, except share data)


· · · · · · · · · · Accumulated · · · · · ·
· · · · · · · Additional · · Other · · · · · Total
· · Ordinary Shares · · Paid‑in · · Comprehensive · · Accumulated · · Shareholders’
· · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Equity
Balance at December 31, 2025	69,367,896	$894	$1,512,339	$(3,505)	$(899,751)	$609,977
Issuance of ADSs upon exercise of share options	3,861	—	7	—	—	7
Issuance of ADSs upon settlement of restricted share units	335,269	5	—	—	—	5
Share-based compensation expense	—	—	6,930	—	—	6,930
Foreign currency translation adjustment	—	—	—	(1,774)	—	(1,774)
Net loss	—	—	—	—	(60,825)	(60,825)
Balance at March 31, 2026	69,707,026	899	1,519,276	(5,279)	(960,576)	554,320
Issuance of ADSs upon exercise of share options	2,920	—	—	—	—	—
Issuance of ADSs upon settlement of restricted share units	104,199	1	—	—	—	1
Share-based compensation expense	—	—	6,404	—	—	6,404
Foreign currency translation adjustment	—	—	—	(137)	—	(137)
Net loss	—	—	—	—	(50,333)	(50,333)
Balance at June 30, 2026	69,814,145	900	1,525,680	(5,416)	(1,010,909)	510,255
Issuance of ADSs upon exercise of share options	9,251	—	—	—	—	—
Issuance of ADSs upon settlement of restricted share units	169,617	3	—	—	—	3
Share-based compensation expense	—	—	5,418	—	—	5,418
Foreign currency translation adjustment	—	—	—	79	—	79
Net loss	—	—	—	—	(10,478)	(10,478)
Balance at September 30, 2026	69,993,013	$903	$1,531,098	$(5,337)	$(1,021,387)	$505,277

Condensed Consolidated Statements of Shareholders’ Equity

(In thousands, except share data)


· · · · · · · · · · Accumulated · · · · · ·
· · · · · · · Additional · · Other · · · · · Total
· · Ordinary Shares · · Paid‑in · · Comprehensive · · Accumulated · · Shareholders’
· · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Equity
Balance at December 31, 2024	69,061,418	$890	$1,472,842	$119	$(680,791)	$793,060
Issuance of ADSs upon settlement of restricted share units	140,937	2	—	—	—	2
Share-based compensation expense	—	—	9,605	—	—	9,605
Foreign currency translation adjustment	—	—	—	(1,580)	—	(1,580)
Net loss	—	—	—	—	(60,754)	(60,754)
Balance at March 31, 2025	69,202,355	892	1,482,447	(1,461)	(741,545)	740,333
Issuance of ADSs upon settlement of restricted share units	51,589	1	—	—	—	1
Share-based compensation expense	—	—	9,435	—	—	9,435
Foreign currency translation adjustment	—	—	—	(1,902)	—	(1,902)
Net loss	—	—	—	—	(78,952)	(78,952)
Balance at June 30, 2025	69,253,944	893	1,491,882	(3,363)	(820,497)	668,915
Issuance of ADSs upon settlement of restricted share units	52,567	1	—	—	—	1
Share-based compensation expense	—	—	8,771	—	—	8,771
Foreign currency translation adjustment	—	—	—	(108)	—	(108)
Net loss	—	—	—	—	(59,100)	(59,100)
Balance at September 30, 2025	69,306,511	$894	$1,500,653	$(3,471)	$(879,597)	$618,479

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.